You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復星醫藥(02196.HK)回吐逾半成重失10天線 首季盈利倒退逾45%
復星醫藥(02196.HK)首季盈利倒退,該股終止兩連漲,今天一舉失守10天、50天及100天線(33-33.75元),最低見31元,現報32.7元,回吐5.4%,成交1,285萬股;復星A股(600196.SH)也結束三連漲,股價回吐5.3%曾低見41.3元人民幣。 復星醫藥公佈,按中國會計準則,今年首季純利按年倒退45.4%至4.63億元人民幣,主要受累於所持BioNTech(BNTX.US)股票等金融資產股價下降導致非經常性損益減少5.27億元人民幣。期內,總營收按年升約29%至103.82億元人民幣。 德國《明鏡週刊》日前報道,隨着上海等多地新冠疫情擴散,中國考慮引入輝瑞(PFE.US)與BioNTech所生產「復必泰」疫苗,改變原本只使用國產疫苗立場,消息刺激復星過去兩天股價累彈逾一成兼成交增加。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account